Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.
| Revenue (TTM) | $14.14B |
| Gross Profit (TTM) | $4.08B |
| EBITDA | $2.25B |
| Operating Margin | 11.00% |
| Return on Equity | 11.10% |
| Return on Assets | 5.31% |
| Revenue/Share (TTM) | $170.67 |
| Book Value | $106.06 |
| Price-to-Book | 2.79 |
| Price-to-Sales (TTM) | 1.75 |
| EV/Revenue | 2.163 |
| EV/EBITDA | 14.83 |
| Quarterly Earnings Growth (YoY) | 32.90% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $82.00M |
| Float | $81.60M |
| % Insiders | 0.35% |
| % Institutions | 101.10% |
Volatility is currently expanding
Besides Wall Street's top-and-bottom-line estimates for Labcorp (LH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers can now access biomarker and hereditary genetic testing from a single source through Labcorp OnDemand BURLINGTON, N.C., July 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of Marker by Labcorp™ Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions.
Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, specialty testing and new collaborations drive momentum.
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Labcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laboratory testing industry for steady, predictable growth. Automation is driving cost reductions in LH's operations. That cost reduction helps offset healthcare pricing pressures. With a larger scale, LH now targets single-digit growth and a total return around 10%, prioritizing predictability over rapid expansion.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LH and any ticker you trade — then tracks every position and per-strategy win rate.
